Key result
Roflumilast administration in pigs induced dose-dependent vascular injury and increased peripheral blood levels of microparticles and specific proteins (p < .05 vs. controls).
Why the study?
Does a single administration of roflumilast induce vascular damage and alter surrogate biomarkers in pigs?
Does a single administration of roflumilast induce vascular damage and alter surrogate biomarkers in pigs?
p-value: p=<0.05
Roflumilast induces acute vascular injury in a pig model, which can be detected by novel peripheral blood biomarkers including microparticles and specific proteins.
Drug-induced vascular injury (DIVI) is commonly associated with phosphodiesterase (PDE) inhibitors. Despite histological characterization, qualified biomarkers for DIVI detection are lacking. We investigated whether a single administration of roflumilast (PDE-IV inhibitor) induces vascular damage and identified novel surrogate biomarkers of acute vascular injury. Pigs received postoperative 250, 375, or 500 μg of roflumilast or placebo/control. After 1.5 hr, coronary reactivity was determined by catheter-based administration of acetylcholine and sodium nitroprusside (SNP) in the coronary sinus. Immunohistochemical analysis of vessel integrity (von Willebrand factor [vWF]) and fibrin(ogen) deposition was performed in the coronary artery and aorta. Peripheral blood was collected for differential proteomics and microparticles analysis. Circulating interleukin (IL)-6 was analyzed. Roflumilast-treated animals displayed higher vasodilation to acetylcholine and SNP versus controls (p < .05). Roflumilast-treated animals showed a dose-dependent (p < .05) decrease in vessel integrity and dose-dependent increase in fibrin deposition forming a continuous layer at roflumilast-500 μg. Peripheral blood of roflumilast-500-μg-treated animals showed increased levels of total and endothelial-derived microparticles and exhibited a coordinated change in proteins kininogen-1, endothelin-1, gelsolin, apolipoprotein A-I, and apolipoprotein-J associated with vascular injury (p < .05 vs. controls). IL-6 remained unaltered. Roflumilast-induced vascular injury can be detected by novel markers in peripheral blood. Validation of these surrogate markers in human samples seems required.
No takes yet. Share an insight, caveat, or question.
Vilahur et al. (2014) studied Drug-induced vascular injury. Roflumilast vs. placebo/control was evaluated on Vascular damage and surrogate biomarkers of acute vascular injury (p=<0.05). Roflumilast administration in pigs induced dose-dependent vascular injury and increased peripheral blood levels of microparticles and specific proteins (p < .05 vs. controls).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: